| Patient | Lili Boulanger |
|---|---|
| Date of birth | 1893-08-21 |
| Identifiers | MRN HR-ET025-SYN-TD; SSN (made up) 000-25-7731 |
| Document date | 1915-03-02 |
| Author | Odile Marchetti-Rowe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review at week 4 of risankizumab, on the day of the second infusion. [S]
Ms. Boulanger had her first risankizumab infusion and intravenous iron four weeks ago without reaction and has her second infusion today. Her stools are down to two or three a day, soft, with no night-time stool, and the cramps are mild (Harvey-Bradshaw Index 5). She is on 20 mg of prednisone, falling to 15 mg this week, and has noticed a rounder face and lighter sleep. She has gained 1.6 kg with the supplements. The mycobacterial culture from her biopsies shows no growth after five weeks; the final report is due next week. She is rehearsing for her concert at the end of the month and composing most mornings. [S]
| Element | Detail |
|---|---|
| Interval change | Risankizumab dose 1 and iron infusion four weeks ago; dose 2 today |
| Activity | Harvey-Bradshaw Index 5, down from 11 |
| Prednisone | 20 mg, tapering as planned; mild sleep disturbance |
| Tuberculosis | Mycobacterial culture: no growth at five weeks |
| Work | Rehearsing for the March concert |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever; energy improving |
| Gastrointestinal | Positive | Two or three soft stools a day; mild cramps; no blood |
| Integumentary | Negative | No rash; no yellowing of the skin |
| Endocrine | Positive | Rounder face on prednisone; no excessive thirst |
| Psychiatric | Positive | Lighter sleep on prednisone; mood better; PHQ-9 5, GAD-7 6 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugs | One or two tablets up to every 6 hours as needed | Oral route | 1914-12-15 | active | S |
| Prednisone 20 mg oral tablet: 40 mg by mouth each morning, reduced by 5 mg each week over eight weeks, as a bridge until risankizumab takes effect | 40 mg each morning, tapering by 5 mg weekly | Oral route | 1915-01-28 to 1915-03-24 | completed | S |
| Risankizumab 600 mg in 10 mL intravenous infusion over at least one hour at weeks 0, 4, and 8 (induction) | One infusion every 4 weeks for three doses | Intravenous route | 1915-02-02 to 1915-04-26 | completed | S |
| Ferric derisomaltose 1000 mg in 10 mL intravenous infusion, single dose | Single infusion | Intravenous route | 1915-02-02 to 1915-02-02 | completed | S |
| Cholecalciferol (vitamin D3) 1889 units oral tablet, one tablet by mouth once daily | One tablet once daily | Oral route | 1915-01-28 | active | S |
| Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet by mouth once daily with food while on prednisone | One tablet daily with food | Oral route | 1915-01-28 to 1915-03-24 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1915-03-02 | Body height | 160 | cm | S |
| 1915-03-02 | Body weight | 46.4 | kg | S |
| 1915-03-02 | Body mass index (BMI) [Ratio] | 18.1 | kg/m2 | S |
| 1915-03-02 | Systolic blood pressure | 108 | mm[Hg] | S |
| 1915-03-02 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1915-03-02 | Heart rate | 84 | /min | S |
| 1915-03-02 | Respiratory rate | 14 | /min | S |
| 1915-03-02 | Body temperature | 36.8 | Cel | S |
| 1915-03-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1915-03-02 | Hemoglobin [Mass/volume] in Blood | 11.6 | g/dL | 12-15.5 g/dL | Low | S |
| 1915-03-02 | C reactive protein [Mass/volume] in Serum or Plasma | 8 | mg/L | <=5 mg/L | High | S |
| 1915-03-02 | Albumin [Mass/volume] in Serum or Plasma | 3.7 | g/dL | 3.5-5 g/dL | Normal | S |
| 1915-03-02 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | <=33 U/L | Normal | S |
| 1915-03-02 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | <=32 U/L | Normal | S |
| 1915-03-02 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | <=1.2 mg/dL | Normal | S |
| 1915-03-02 | Phosphate [Mass/volume] in Serum or Plasma | 3 | mg/dL | 2.5-4.5 mg/dL | Normal | S |
| 1915-03-02 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 1915-03-02 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 6 | {score} | S |
Vital signs recorded on 1915-03-02; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Brighter; BMI 18.1 |
| Eyes | No jaundice |
| Mouth | Aphthous ulcers healed |
| Abdomen | Mild right lower quadrant tenderness; no fullness |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Crohn disease of the terminal ileum and colon (ileocolitis), Montreal A2 L3 B1 without perianal disease, moderate to severe: deep ileal ulcers over 15 cm and patchy colonic ulcers, SES-CD 14, Harvey-Bradshaw Index 11; intestinal tuberculosis excluded by negative interferon-gamma release assay, normal chest X-ray, and biopsies negative for acid-fast bacilli, TB PCR, and mycobacterial culture; synthetic modern diagnosis linked to her documented chronic intestinal illness, whose historical diagnosis is not settled | active | confirmed | K50.80 | S — Synthetic diagnosis confirmed within the modern episode; her historical illness is documented (D), but whether it was intestinal tuberculosis or Crohn disease remains a retrospective interpretation (R) and is disputed. |
| Four months of crampy right lower abdominal pain, loose stools up to six times a day including at night, low-grade evening fevers, and loss of 6 kg; inflammatory markers raised; colonoscopy and small-bowel imaging booked | resolved | confirmed | R19.7 | S — Synthetic presenting concern at the index visit, superseded by the diagnosis; the documented symptoms of early 1915 are echoed (D). |
| Iron deficiency anemia from chronic intestinal blood loss and poor absorption (hemoglobin 10.6 g/dL, MCV 76, ferritin 9) | active | confirmed | D50.0 | S — Synthetic finding at presentation; corrected by intravenous iron. |
| Moderate protein-calorie malnutrition: BMI 17.6 after losing 6 kg (12 percent of body weight) in four months; albumin 3.3 g/dL | active | confirmed | E44.0 | S — Synthetic nutritional status at presentation; resolved with treatment and dietitian support. |
| Vitamin D deficiency (25-hydroxyvitamin D 18 ng/mL) | active | confirmed | E55.9 | S — Synthetic finding at presentation. |
| Long-term use of risankizumab, an immunosuppressive biologic, for Crohn disease | active | confirmed | Z79.620 | S — Synthetic treatment status. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptoms and Harvey-Bradshaw Index | Every visit | Completed today | 5, down from 11 (clinical response) |
| Laboratory | CRP | Every visit during induction | Completed today | 8 mg/L, down from 38 |
| Laboratory | Liver enzymes and bilirubin during risankizumab induction | Through at least week 12 | Completed today | ALT 22, AST 24, bilirubin 0.5 |
| Laboratory | Hemoglobin and phosphate after intravenous iron | Four weeks after the infusion | Completed today | Hemoglobin 11.6 g/dL; phosphate 3.0 mg/dL |
| Laboratory | Albumin and weight | Every visit | Completed today | Albumin 3.7 g/dL; weight up 1.6 kg |
| Laboratory | Mycobacterial culture of the biopsies | Final result at six to eight weeks | Up to date | No growth at five weeks; final report next week |
| Laboratory | Hepatitis B antibody after the booster | One to two months after the dose | Deferred | Not drawn today, a deviation from the plan: it was left off the order with the infusion blood tests. Rescheduled with the week-12 tests. She has no known exposure and the booster was given, so harm is unlikely; standing orders for post-vaccine antibody checks are now added at the time of the dose |
| Medication safety | Corticosteroid side effects and taper | Every visit on steroids | Completed today | Mild sleep disturbance and facial rounding; taper on schedule |
| Survey | Depression and anxiety screen (PHQ-9 and GAD-7) | At intervals | Completed today | PHQ-9 5 and GAD-7 6 |
| Laboratory | Fecal calprotectin | About three months after starting treatment | Due | At week 12 |
| Imaging | Ileocolonoscopy for endoscopic response | Six to twelve months after starting treatment | Due | In the autumn |
Goal progress:
Guideline basis: ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025); ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025); STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the IOIBD. Gastroenterology 2021;160:1570-1583 (2021); SKYRIZI (risankizumab-rzaa): prescribing information (Crohn disease dosing; hepatotoxicity monitoring; tuberculosis evaluation; immunizations) (2026)
Follow-up: Third infusion at week 8. Review at week 12, the first maintenance dose. Next scheduled visit 1915-04-27: review at week 12, the first maintenance dose of risankizumab. [S]